Add Company
Join Now

Capstone Therapeutics Revenue and Competitors

License our Company Data API

Phoenix, AZ USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Capstone Therapeutics's estimated annual revenue is currently $1.6M per year.(i)
  • Capstone Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Capstone Therapeutics has 10 Employees.(i)
  • Capstone Therapeutics grew their employee count by 0% last year.

Capstone Therapeutics's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Executive Chairman and Principal Executive OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M50%N/AN/A
#2
$0.9M60%N/AN/A
#3
$0.8M5-29%N/AN/A
#4
$5.3M340%N/AN/A
#5
$2.5M16-20%N/AN/A
#6
$1.1M70%N/AN/A
#7
$0.9M60%N/AN/A
#8
$2.2M2921%$58.2MN/A
#9
$171.9M1109-3%N/AN/A
#10
$0.9M60%N/AN/A
Add Company

What Is Capstone Therapeutics?

Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.8M10-23%N/A
#2
$2M10-50%N/A
#3
$1.5M10-62%N/A
#4
$1.8M10-68%N/A
#5
$0.9M100%N/A